COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies.
Compass is a clinical-stage biotechnology company focused on developing psychedelics-based drugs for neuropsychiatric disorders. The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s ...
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today ...
Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 ...
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other ...
COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...
Psilocybin-assisted therapy is legal in three states, but access has so far been limited and expensive. In the billion-dollar race to commercialize psychedelic medicine, psilocybin, a naturally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback